Clinical trials: Psilocybin
Major Depressive Disorder, Depression
The Effect of Psilocybin on MDD Symptom Severity and Synaptic Density
PROTOCOL SYNOPSIS Title The effect of psilocybin on Major depressive disorder (MDD) symptom severity and synaptic density - a single dose randomized, double blind, placebo-controlled phase 2b positron emission tomography study…
- Trial name
- PSIPET (NCT04630964)
- Testing
- Psilocybin, Niacin
- Where
- Sweden
- Volunteers
- 35 people
- Sponsor
- Section for Affective Disorders; Northern Stockholm Psychiatry
Obsessive-compulsive Disorder (OCD)
Psilocybin for Treatment of Obsessive Compulsive Disorder
This study will evaluate whether psilocybin, a hallucinogenic drug, improves symptoms of obsessive compulsive disorder (OCD), whether it is safely tolerated as treatment of OCD, and will investigate the mechanisms by which it…
- Trial name
- PSILOCD (NCT03300947)
- Testing
- Psilocybin 100 mcg/kg, Psilocybin 300 mcg/kg, Lorazepam 1 mg
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- University of Arizona
Migraine
Mechanistic Studies of Psilocybin in Headache Disorders
In previous clinical trial work, the investigators observed lasting reductions in headache burden after limited dosing of psilocybin. This purpose of this study is to examine potential sources for this observed effect.
- Trial name
- NCT06464367
- Testing
- Psilocybin
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Yale University
Caregiver Distress
Psilocybin-assisted Existential, Attachment and RelationaL (PEARL) Therapy for Caregivers of Patients With Advanced Cancer
The PEARL-C1 trial is a phase II open-label trial. Participants will receive a single high-dose (25 mg) of psilocybin in the context of Psilocybin-assisted Existential, Attachment and RelationaL (PEARL) therapy.
- Trial name
- PEARL-C1 (NCT07048743)
- Testing
- Psilocybin
- Where
- Canada
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- University Health Network, Toronto
Fibromyalgia, Primary
Psilocybin-facilitated Treatment for Chronic Pain
The primary purpose of this study is to preliminarily estimate the efficacy of psilocybin-facilitated treatment for fibromyalgia.
- Trial name
- NCT05068791
- Testing
- Psilocybin, Dextromethorphan
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Alabama at Birmingham
Opioid Use Disorder
Inpatient Buprenorphine Induction With Psilocybin for Opioid Use Disorder
This study will examine the effect of a single high dose of psilocybin therapy (30 mg) versus a very low dose (1 mg) as an adjunctive therapy to individuals undergoing standard-of-care buprenorphine treatment for Opioid use…
- Trial name
- BIPOD-In (NCT06005662)
- Testing
- Psilocybin
- Where
- United States
- Sponsor
- Johns Hopkins University
Amphetamine-Related Disorders
Psilocybin-Enhanced Psychotherapy for Methamphetamine Use Disorder
This is a proof-of-concept randomized clinical trial of psilocybin-enhanced psychotherapy versus treatment-as-usual among individuals being treated for methamphetamine use disorder.
- Trial name
- NCT04982796
- Testing
- Psilocybin, Treatment-as-usual
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Portland VA Research Foundation, Inc
Transdiagnostic, Depression - Major Depressive Disorder
Open-Label Psilocybin Study in Transdiagnostic Population
The primary objective of this study is to investigate the safety, feasibility, and tolerability of psilocybin treatment in individuals with functional impairment due to psychiatric symptoms.
- Conditions
- Transdiagnostic, Depression - Major Depressive Disorder, Anxiety, PTSD Symptoms
- Trial name
- NCT06442423
- Testing
- Psilocybin
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Yale University
Personality
Personality and Drug Use (PDU)
The study aims to assess whether the use of drugs relates to personality ratings. Specifically, we plan to investigate if people with different histories of substance use differentiate on personality assessments (current and…
- Trial name
- PDU (NCT05180149)
- Volunteers
- healthy volunteers welcome
- Sponsor
- Quantified Citizen Technologies Inc.
Depression, Burnout, Professional
PAPR: PAP + MBSR for Front-line Healthcare Provider COVID-19 Related Burnout
This project is an open-label randomized study looking at an 8-week Mindfulness-Based Stress Reduction (MBSR) curriculum vs. an 8-week MBSR curriculum + a group psilocybin-assisted psychotherapy intervention for frontline…
- Trial name
- PAPR (NCT05557643)
- Testing
- Psilocybin, Mindfulness-Based Stress Reduction (MBSR)
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- University of Utah
Amnestic Mild Cognitive Impairment
Does Psilocybin Change Synaptic Density in Amnestic Mild Cognitive Impairment
The goal of this pilot, exploratory, clinical trial is to investigate the effects of psilocybin on synaptic vesicular density (SVD) as measured by the positron emission tomography (PET) radiotracer, 18F-SynVesT-1, in participants…
- Trial name
- NCT06041152
- Testing
- Psilocybin
- Where
- Canada
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Centre for Addiction and Mental Health
Advanced Cancer, Demoralization
MB-PAT for Demoralization in Advanced Cancer ('PAT-MIND') Trial
This pilot clinical trial will study psilocybin-assisted therapy for adults with advanced cancer who are experiencing demoralization, existential distress, or related psychological concerns.
- Conditions
- Advanced Cancer, Demoralization, Existential Distress, Psychological Distress
- Trial name
- PAT-MIND (NCT07791901)
- Testing
- PEX010 25 mg psilocybin, PEX010 5 mg psilocybin, Standard Psilocybin-Assisted Therapy
- Where
- 2 sites in Canada
- Volunteers
- 60 people
- Sponsor
- University of Calgary
Refractory Depression, Treatment Resistant Depression
Psilocybin-Assisted Therapy in Treatment-Resistant Depression
The goal of this clinical trial is to test how well psilocybin-assisted therapy works in treating people with depression. The main questions this study aims to answer are: Does psilocybin with assisted therapy help improve…
- Trial name
- NCT06303739
- Testing
- psilocybin
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of North Carolina, Chapel Hill
Major Depressive Disorder
Psilocybin-assisted CBT for Depression
The primary objectives of this clinical investigation are to (1) determine the acceptability and feasibility of joining psilocybin-assisted therapy with cognitive-behavioral therapy (PA-CBT) for patients with depression, (2)…
- Trial name
- NCT05227612
- Testing
- Psilocybin, Cognitive behavioral therapy
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- University of California, Los Angeles
Healthy
Direct Comparison of Altered States of Consciousness Induced by LSD, Psilocybin, and DMT in Healthy Participants
The primary objective of this study is to determine whether equivalent moderately high doses of LSD, psilocybin, and DMT produce qualitatively similar peak effects when the effect duration is standardized with ketanserin.
- Trial name
- LPD (NCT06899334)
- Testing
- LSD, Psilocybin, DMT
- Where
- Switzerland
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- University Hospital, Basel, Switzerland
Healthy Volunteers, Major Depressive Disorder
ELE-101 Safety & Tolerability Study in Healthy Participants and Patients With Depression
A study to assess the safety and tolerability of a drug called ELE-101 and see how the body absorbs and removes the drug and how it affects the body in healthy adult participants (Part 1) and in patients with depression (Part 2).
- Conditions
- Healthy Volunteers, Major Depressive Disorder, Depression
- Trial name
- NCT05434156
- Testing
- ELE-101
- Where
- 2 sites in United Kingdom
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Eleusis Therapeutics
Body Dysmorphic Disorders
Safety and Efficacy of Psilocybin for Body Dysmorphic Disorder
In this pilot study 12 adult outpatients with body dysmorphic disorder that has not responded to at least one adequate trial of a serotonin reuptake inhibitor will be treated openly with a single oral dose of psilocybin.
- Trial name
- NCT04656301
- Testing
- Psilocybin
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- New York State Psychiatric Institute
Depressive Disorder, Major
Psilocybin for Major Depressive Disorder (MDD)
Approximately 240 eligible adult participants (≥18 years old) who meet Diagnostic and Statistical Manual of Mental Disorders (DSM-5-TR) criteria for Major Depressive Disorder (MDD) will be enrolled.
- Trial name
- uAspire (NCT06308653)
- Testing
- Psilocybin 25 mg, Psilocybin 5 mg, Psychosocial Support
- Where
- 29 sites in United States
- Volunteers
- 238 people
- Sponsor
- Usona Institute
Healthy
Effects of Psilocybin-facilitated Experience on the Psychology and Effectiveness of Professional Leaders in Religion
The current protocol is a pilot study of the effects and possible utility of psilocybin-facilitated experiences for professional religious leaders.
- Trial name
- NCT02243813
- Testing
- Psilocybin
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
Trauma, Nervous System
Northwest Therapies Trauma Psilocybin Study Compassionate Use Study
The on-boarding of unregulatable trauma in the United States has reached 20%, which is 1/5 of the population. A population of this magnitude, by definition has now reached an epidemic classification.
- Trial name
- NWTTPS (NCT05042466)
- Testing
- Trauma
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- NWTraumatherapies